PLCD3

Across TCGA pan-cancer cohorts, PLCD3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PLCD3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where PLCD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PLCD3 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

COAD, LUAD, and LSCC are the cancer types where PLCD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	−0.584	<.001	11	view →
LUAD	Female	All	−0.986	<.001	9	view →
LSCC	Female	All	−0.735	<.001	8	view →
HNSC	Male	All	−0.385	<.001	8	view →
PDAC	Female	All	+0.607	<.001	7	view →
CCRCC	All	All	+0.148	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PLCD3–COAD

Open the COAD breakdown →